Astrocytic lactoferrin deficiency augments MPTP-induced dopaminergic neuron loss by disturbing ER-mitochondria signaling

Shuang-Feng Xu,Zhong-Qiu Pang,Chen-Yang Bai,Meng-Yu Jia,Jun-He Cui,Zhuo-Jue Wang,Xiu-Ting Liang,Chuang Guo
DOI: https://doi.org/10.21203/rs.3.rs-1558216/v1
2022-01-01
Abstract:Abstract Increased levels of lactoferrin (Lf) are present in the aged brain and in the lesions of various neurodegenerative diseases, including Parkinson’s disease (PD), may contribute to the cascade of events involved in neurodevelopment and neuroprotection. However, whether Lf originates from astrocytes and functions within either the normal or pathological brain are unknown. Here, we employed mice with specific knockout of the astrocyte Lf gene (named Lf-cKO) to explore its specific roles in the pathological process of PD. We observed a decrease in tyrosine hydroxylase (TH)-positive cells, mitochondrial dysfunction of residual dopaminergic neurons, and motor deficits in Lf-cKO mice, which were significantly aggravated after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. To further explore how astrocytic Lf deficiency exacerbated PD-like manifestation in MPTP-treated mice, the critical molecules involved in endoplasmic reticulum (ER)-mitochondria contacts and signaling pathways were investigated. In in vitro and in vivo models, we found an aberrant level of effects implicated in reactive oxygen species (ROS) production, apoptosis, mitochondrial morphology and functions, mitochondrial dynamics, mitochondria-associated ER membranes (MAMs), lipid metabolism, and calcium homeostasis, accompanied by signs of ER stress, which increase the fragility of dopaminergic neurons. These findings confirm the existence of astrocytic Lf and its influence on the fate of dopaminergic neurons by regulating ER-mitochondria signaling. Our findings may be a promising target for the treatment of PD.
What problem does this paper attempt to address?